166 related articles for article (PubMed ID: 20521216)
1. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
Ware N; MacPhee IA
Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
[TBL] [Abstract][Full Text] [Related]
2. Use of pharmacogenetics to optimize immunosuppressive therapy.
Macphee IA
Ther Drug Monit; 2010 Jun; 32(3):261-4. PubMed ID: 20431509
[TBL] [Abstract][Full Text] [Related]
3. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
van Gelder T; Hesselink DA
Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic biomarkers: cytochrome P450 3A5.
MacPhee IA
Clin Chim Acta; 2012 Sep; 413(17-18):1312-7. PubMed ID: 22037511
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies.
Anglicheau D; Legendre C; Thervet E
Transplant Proc; 2007 Sep; 39(7):2142-4. PubMed ID: 17889118
[TBL] [Abstract][Full Text] [Related]
6. Optimization of initial tacrolimus dose using pharmacogenetic testing.
Thervet E; Loriot MA; Barbier S; Buchler M; Ficheux M; Choukroun G; Toupance O; Touchard G; Alberti C; Le Pogamp P; Moulin B; Le Meur Y; Heng AE; Subra JF; Beaune P; Legendre C
Clin Pharmacol Ther; 2010 Jun; 87(6):721-6. PubMed ID: 20393454
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.
Ekbal NJ; Holt DW; Macphee IA
Pharmacogenomics; 2008 May; 9(5):585-96. PubMed ID: 18466104
[TBL] [Abstract][Full Text] [Related]
8. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
Kuypers DR
Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
[No Abstract] [Full Text] [Related]
10. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
13. [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].
Fukudo M
Yakugaku Zasshi; 2007 Jul; 127(7):1081-9. PubMed ID: 17603267
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
[TBL] [Abstract][Full Text] [Related]
15. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
Wang J
Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
[TBL] [Abstract][Full Text] [Related]
16. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
[TBL] [Abstract][Full Text] [Related]
17. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.
Kniepeiss D; Renner W; Trummer O; Wagner D; Wasler A; Khoschsorur GA; Truschnig-Wilders M; Tscheliessnigg KH
Clin Transplant; 2011; 25(1):146-50. PubMed ID: 20041908
[TBL] [Abstract][Full Text] [Related]
18. Practicability of pharmacogenetics in transplantation medicine.
van Gelder T; van Schaik RH; Hesselink DA
Clin Pharmacol Ther; 2014 Mar; 95(3):262-4. PubMed ID: 23995265
[TBL] [Abstract][Full Text] [Related]
19. Genetic factors for individual administration of immunosuppressants in organ transplantation.
Yu SF; Wu LH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):337-44. PubMed ID: 16911928
[TBL] [Abstract][Full Text] [Related]
20. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
